Positions

Overview

  • Dr. Marrazzo is Professor of Medicine and Director of the Division of Infectious Diseases at the University of Alabama at Birmingham. She is internationally recognized for her research and education efforts in the field of sexually transmitted infections, especially as they affect women’s health. She is a Fellow of the American College of Physicians and of the Infectious Diseases Society of America. Dr. Marrazzo has chaired the American Board of Internal Medicine (ABIM) Council, and the ABIM Infectious Disease Specialty Board. She is board certified in Infectious Disease.
    She conducts research on the human microbiome, specifically as it relates to female reproductive tract infections and hormonal contraception. Her other research interests include prevention of HIV infection using biomedical interventions, including PrEP and microbicides. Other research interests include pathogenesis and management of bacterial vaginosis, sexually transmitted diseases in HIV-infected persons, and management of antibiotic resistance in gonorrhea.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Cabotegravir for HIV prevention in cisgender men and transgender womenNew England Journal of Medicine.  385:595-608. 2021
    2021 Genetic variation in toll-like receptor 5 and colonization with flagellated bacterial vaginosis-associated bacteriaInfection and Immunity.  89. 2021
    2021 Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girlsAIDS.  35:369-380. 2021
    2020 High rates of persistent and recurrent chlamydia in pregnant women after treatment with azithromycin 2020
    2020 Decreasing High Risk Exposures for Healthcare-workers through Universal Masking and Universal SARS-CoV-2 Testing upon entry to a Tertiary Care Facility.Clinical Infectious Diseases2020
    2020 Annals On Call - Diagnosing SARS-CoV-2 Infection: Symptoms or No Symptoms?Annals of Internal Medicine.  173:OC1. 2020
    2020 Behavioral Counseling for Sexually Transmitted Infection Risk Reduction 2020
    2020 Cervicitis: Balancing the Goals of Empiric Therapy and Antimicrobial Stewardship to Improve Women's HealthSexually Transmitted Diseases.  47:387-388. 2020
    2020 Annals On Call - Protecting Health Care Workers From COVID-19Annals of Internal Medicine.  172:OC1. 2020
    2019 Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trialLancet HIV.  6:e498-e508. 2019
    2019 Tenofovir gel for prevention of herpes simplex virus type 2 acquisition: Findings from the VOICE trialJournal of Infectious Diseases.  219:1940-1947. 2019
    2019 The Evolving Facets of Bacterial Vaginosis: Implications for HIV TransmissionAIDS Research and Human Retroviruses.  35:219-228. 2019
    2019 HIV status and other risk factors for prevalent and incident sexually transmitted infection during pregnancy (2000-2014) 2019
    2018 Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrheaNew England Journal of Medicine.  379:1835. 2018
    2018 Health Care Provider Perceptions of a Sexually Transmitted Infection Self-testing Program in an HIV Care ClinicSexually Transmitted Diseases.  45:417-421. 2018
    2017 The fourth generation AlereTM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samplesJournal of Clinical Virology.  94:15-21. 2017
    2017 Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair ConcentrationsAIDS Research and Human Retroviruses.  33:778-783. 2017
    2017 HIVR4P 2016, Partnering for Prevention: Conference Summary and HighlightsAIDS Research and Human Retroviruses.  33:749-759. 2017
    2017 Contraceptive Use and Pregnancy Incidence among Women Participating in an HIV Prevention TrialJournal of Women's Health.  26:670-676. 2017
    2017 Validity of self-reported history of Chlamydia trachomatis infection 2017
    2017 Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented MinoritiesJournal of Infectious Diseases.  216:S606-S610. 2017
    2016 A conversation among the IAS–USA board of directors: Hot topics and emerging data in HIV research and careTopics in antiviral medicine.  24:142-151. 2016
    2016 HIV prevention: Opportunities and challengesTopics in antiviral medicine.  24:123-126. 2016
    2016 HIV prevention: Opportunities and challengesTopics in antiviral medicine.  24:123-126. 2016
    2016 More Easily Cultivated Than Identified: Classical Isolation with Molecular Identification of Vaginal BacteriaJournal of Infectious Diseases.  214:S21-S28. 2016
    2016 Rapid Diagnosis of Trichomonas vaginalis by Testing Vaginal Swabs in an Isothermal Helicase-Dependent AmpliVue AssaySexually Transmitted Diseases.  43:369-373. 2016
    2016 Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study 2016
    2016 Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE studyJournal of Infectious Diseases.  213:335-342. 2016
    2016 Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis 2016
    2015 Disclosure of pharmacokinetic drug results to understand nonadherenceAIDS.  29:2161-2171. 2015
    2015 Barriers to bacterial sexually transmitted infection testing of HIV-infected men who have sex with men engaged in HIV primary careSexually Transmitted Diseases.  42:590-594. 2015
    2015 Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young WomenAmerican Journal of Reproductive Immunology.  74:323-332. 2015
    2015 Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosisJournal of Infectious Diseases.  212:793-802. 2015
    2015 A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosisSexually Transmitted Diseases.  42:376-381. 2015
    2015 Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: A prospective cohort studyLancet HIV.  2:e279-e287. 2015
    2015 Women who have sex with women living in low- and middle-income countries: A systematic review of sexual health and risk behaviorsLGBT Health.  2:91-104. 2015
    2015 Metabolic signatures of bacterial vaginosismBio.  6. 2015
    2015 Advancing care for lesbian, gay, bisexual, and transgender persons: Enough already?Annals of Internal Medicine.  163:143-144. 2015
    2015 Tenofovir-based preexposure prophylaxis for HIV infection among African womenObstetrical and Gynecological Survey.  70. 2015
    2015 What's new in sexually transmitted infections in the hiv care setting: Focus on syphilis and gonorrheaTopics in antiviral medicine.  22:698-701. 2015
    2014 Recent advances in understanding and managing Chlamydia trachomatis infections 2014
    2014 HIV prevention in clinical care settings: 2014 Recommendations of the International Antiviral Society-USA Panel 2014
    2014 Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1 2014
    2014 Improving HIV/STD prevention in the care of persons living with HIV through a national training programAIDS Patient Care and STDS.  28:15-21. 2014
    2013 More Than Meets the Eye: Associations of Vaginal Bacteria with Gram Stain Morphotypes Using Molecular Phylogenetic Analysis 2013
    2013 Population-Level Benefits from Providing Effective HIV Prevention Means to Pregnant Women in High Prevalence Settings 2013
    2013 Vaginal biofilms and bacterial vaginosis: Of mice and womenJournal of Infectious Diseases.  207:1481-1483. 2013
    2012 Mucosal escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trialJournal of Infectious Diseases.  206. 2012
    2012 Bacterial communities in women with bacterial vaginosis: High resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria 2012
    2012 Emerging sexual health issues among women who have sex with womenCurrent Infectious Disease Reports.  14:204-211. 2012
    2012 Chlamydia positivity in women screened in family planning clinics: Racial/ethnic differences and trends in the Northwest U.S., 1997-2006Public Health Reports.  127:38-51. 2012
    2011 Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators 2011
    2011 Interpreting the epidemiology and natural history of bacterial vaginosis: Are we still confused? 2011
    2011 Establishing and sustaining a healthy vaginal environment: Analysis of data from a randomized trial of periodic presumptive treatment for vaginal infectionsJournal of Infectious Diseases.  204:323-326. 2011
    2010 Prevalence and risks for bacterial vaginosis in women who have sex with womenSexually Transmitted Diseases.  37:335-339. 2010
    2010 Walter E. Stamm, MD, 1945-2009Sexually Transmitted Diseases.  37:281-282. 2010
    2009 Preferred characteristics of vaginal microbicides in women with bacterial vaginosisJournal of Women's Health.  18:1163-1167. 2009
    2009 Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR 2009
    2009 Distribution of genital Lactobacillus strains shared by female sex partnersJournal of Infectious Diseases.  199:680-683. 2009
    2009 Sexually transmitted infections and associated conditions among women who have sex with womenOpen Infectious Diseases Journal.  3:128-134. 2009
    2008 Chlamydia positivity in american Indian/Alaska native women screened in family planning clinics, 1997-2004Sexually Transmitted Diseases.  35:753-757. 2008
    2008 Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosisApplied and Environmental Microbiology.  74:4898-4909. 2008
    2008 Routine HIV testing in the context of syndromic management of sexually transmitted infections: Outcomes of the first phase of a training programme in BotswanaSexually Transmitted Infections.  84:259-264. 2008
    2007 Emerging issues in management of sexually transmitted diseases in HIV infectionCurrent Infectious Disease Reports.  9:518-530. 2007
    2007 Population-based outreach for chlamydia screening in men: Results from a randomized trialSexually Transmitted Diseases.  34:837-839. 2007
    2007 Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis 2007
    2007 Within the hidden epidemic: Sexually transmitted diseases and HIV/AIDS among American Indians and Alaska nativesSexually Transmitted Diseases.  34:767-777. 2007
    2007 Selective testing criteria for gonorrhea among young women screened for chlamydial infection: Contribution of race and geographic prevalenceJournal of Infectious Diseases.  196:731-737. 2007
    2007 Correlates of sexually transmitted infections in young women [1]Journal of Infectious Diseases.  195:303. 2007
    2007 Syphilis and other sexually transmitted diseases in HIV infection. 2007
    2006 Women's satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosisJournal of Women's Health.  15:1053-1060. 2006
    2005 Molecular identification of bacteria associated with bacterial vaginosisNew England Journal of Medicine.  353:1899-1911. 2005
    2005 Cervical specimen order and performance measures of Chlamydia trachomatis diagnostic testing 2005
    2005 Dangerous assumptions: Lesbians and sexual deathSexually Transmitted Diseases.  32:570-571. 2005
    2005 Impact of patient characteristics on performance of nucleic acid amplification tests and DNA probe for detection of Chlamydia trachomatis in women with genital infections 2005
    2005 Prevalence of Chlamydia trachomatis infection among men screened in 4 U.S. citiesSexually Transmitted Diseases.  32:74-77. 2005
    2004 Evolving issues in understanding and treating bacterial vaginosis 2004
    2004 Reproductive health history of lesbians: Implications for care 2004
    2003 Functional characterization of class Ia- and non-class Ia-restricted Chlamydia-reactive CD8+ T cell responses in humansJournal of Immunology.  171:4278-4286. 2003
    2003 Vulvovaginal candidiasis 2003
    2003 Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic reviewObstetrical and Gynecological Survey.  58:351-358. 2003
    2003 The clinical and economic consequences of screening young men for genital chlamydial infectionSexually Transmitted Diseases.  30:99-106. 2003
    2003 Candidiasis (vulvovaginal). 2003
    2002 Head-to-head multicenter comparison of DNA probe and nucleic acid amplification tests for Chlamydia trachomatis infection in women performed with an improved reference standard 2002
    2002 Predicting chlamydial and gonococcal cervical infection: Implications for management of cervicitisObstetrics and Gynecology.  100. 2002
    2001 Impact of New Sexually Transmitted Disease Diagnostics on Clinical Practice and Public Health Policy.Current Infectious Disease Reports.  3:147-151. 2001
    2001 Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with womenAmerican Journal of Public Health.  91:947-952. 2001
    2001 Urine-based screening for Chlamydia trachomatis in men attending sexually transmitted disease clinicsSexually Transmitted Diseases.  28:219-225. 2001
    2000 Sexually transmitted infections in women who have sex with women: Who cares?Sexually Transmitted Infections.  76:330-332. 2000
    1998 Genital human papillomavirus infection in women who have sex with womenJournal of Infectious Diseases.  178:1604-1609. 1998
    1995 Chancroid: new developments in an old disease.Current Clinical Topics in Infectious Diseases.  15:129-152. 1995
    Acceptability of urine-based screening for Chlamydia trachomatis in asymptomatic young men: a systematic review.Sexually Transmitted Diseases.  35.
    Interventions to prevent sexually transmitted infections, including HIV infectionClinical Infectious Diseases.  53.
    Missed Prevention Opportunities: Why Young, Black MSM with Recent HIV Diagnosis did not Access HIV Pre-exposure Prophylaxis Services
    Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: A double-blind, randomized, cross-over trialJournal of Infectious Diseases.  212:1949-1956.
    Risk Factors for Incidence of Sexually Transmitted Infections among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003)Sexually Transmitted Diseases.  44:135-140.
    Sexually transmitted infectionsInfectious Disease Clinics of North America.  27:9-10.
    The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.Sexually Transmitted Diseases.  35.

    Chapter

    Year Title Altmetric
    2014 Neisseria gonorrhoeae (Gonorrhea).  2446-2462.e3. 2014
    2013 Bacterial Vaginosis.  463-498. 2013
    2013 Syphilis in Women.  461-471. 2013
    2013 Topical Microbicides for Human Immunodeficiency Virus and Sexually Transmitted Disease Prevention.  213-227. 2013
    2013 Chlamydia trachomatis infection among sexual minorities.  142-150. 2013
    2013 Enhancing women's sexual health: Prevention measures in diverse populations of women.  197-219. 2013
    2012 Bacterial Vaginosis.  54-63. 2012
    2012 Introduction to Sexually Transmitted Infections.  300-302. 2012
    2001 Chlamydiae.  795-822. 2001

    Research Overview

  • Effects of contraceptive ring on vaginal microbiota, HIV shedding and local immunity
    Optimizing Vaginal Ring Pre-Exposure Prophylaxis for HIV
    The Genital Microbiome as a Determinant of Sexual Health & Local Immunity
    The Role of Uncultivated Bacteria in Bacterial Vaginosis
    Vaginal and oral pre-exposure prophylaxis to prevent HIV and HSV-2 infection in women
  • Principal Investigator On

  • 14th Biennial Congress of the Anaerobe Society of the Americas (ASA)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • 75N93019F00131 TA02 TO9 Development of a Protocol, Clinical Trial Implementation, Closeout and Analysis of a Phase 2 Clinical Trial to Evaluate the Eficacy of rMenB+OMV NZ (Bexsero, GSK) in Preventing Neisseria Gonorrhoese Infection  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • 75N93019F00132 TA1 TO15 Overall Administrative and Support Activities for the STI CTG to Include Procedures to Identify, Discuss, and Develop Scientific Concepts  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Drug at the Right Place and Concentration: Optimizing Combination Vaginal Ring PrEP  awarded by ALBERT EINSTEIN COLLEGE OF MEDICINE
  • Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • HPTN Leadership Biomedical Committee Chair  awarded by FHI 360
  • Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)  awarded by Emory University
  • Leadership and Operations Center (LOC): Microbicide Trials Network  awarded by Magee-Womens Research Institute (MWRI)
  • Perceptions of Multipurpose Prevention Technologies Aimed at HIV/STI/unintended pregnancy among African-American Women in the Deep South  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • Post Acute Sequelae of SARS-COV-2 Infection Initiative  awarded by NEW YORK UNIVERSITY SCHOOL OF MEDICINE
  • Private Grant  awarded by CEPHEID
  • Private Grant  awarded by BECTON DICKINSON AND COMPANY
  • STI & HIV 2019 World Congress, The Joint Meeting of the 23rd International Society for Sexually Transmitted Disease Research (ISSTDR) & 20th International Union Against Sexually Transmitted Infections (IUSTI)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Seattle STD Clinical Prevention Training Center  awarded by UNIVERSITY OF WASHINGTON
  • Sexually Transmitted Infections Clinical Trials Group (STI CTG)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • T011 HHSN27200010 TA1 TO9 Protocol Development, Implementation and Analysis for Mycoplasma Genitalium Among Men with Urethritis Attending STD Clinics in the US: Assessing Burden, Risk Factors and Co-Infections  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • T012 HHSN27200011 TA1 TO10 Protocol Development, Implementation and Analysis for Treatment of Gardnerella Vaginalis Vaginal Colonization with Amoxicillin  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • T013 HHSN27200012 TA1 TO11 Overall Admin and Support Activities for the STI CTG to Include Procedures to Identify, Discuss and Develop Scientific Concepts  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • T015 HHSN27200013 TA2 TO7 Protocol Development, Implementation and Analysis for a Randomized Controlled Trial of Azithromycin Versus Doxycycline for the Treatment of Rectal Chlamydia in Men who have Sex with Men  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • T016 HHSN27200014 TA2 TO8 A Phase III Comparative Trial of Benzathine Penicillin G, 2.4 Million Units Administered as a Single Dose Versus Three Sucessive Weekly Doses for Treatment of Early Syphilis in Persons with and without HIV  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • T017 HHSN27200015 TA1 TO13 Protocol Development, Implementation and Analysis for Development and Validating an Easy to Administer Instrument to Define Penicillin (B-lactam) Allergy Status in STD Outpatients  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • T018 HHSN27200016 TA1 TO14 A Randomized, Placebo-Controlled Trial of TOL-463 for Suppression of Bacterial Vaginosis (BV)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • The UAB Sexually Transmitted Infections Cooperative Research Centers (STI CRC)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • The UAB Sexually Transmitted Infections Cooperative Research Centers (STI CRC) - Core A-Administrative Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research -SWG Core - Ending HIV in Alabama SWG  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • University of Washington Sexually Transmitted Infections Cooperative Research Cen  awarded by UNIVERSITY OF WASHINGTON
  • Investigator On

  • A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults  awarded by Emory University
  • A-Z Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • HHSN27200012 Task Area 1 Task Order 11 - Overall Admin and Support Activities for the STI CTG to Include Procedures to Identify, Discuss and Develop Scientific Concepts  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • HHSN27200016 TA1 TO 14 Task Area 1 Task Order 14: A Randomized, Placebo-Controlled Trial of TOL-463 for Suppression of Bacterial Vaginosis (BV)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Increasing Uptake of PrEP in Urban and Rural Black Women in the South  awarded by Johnson (Robert Wood) Foundation
  • Private Grant  awarded by RHEONIX, INC.
  • Private Grant  awarded by ABBOTT MOLECULAR
  • Reducing Vertical Transmission of Hepatitis B in Africa (REVERT-B Trial)  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • Sexually Transmitted Infections Clinical Trials Group (STI CTG)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • The UAB STI CRC - DiSCIS Administrative Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • The UAB Sexually Transmitted Infections Cooperative Research Centers (STI CRC)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research (CFAR)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Administrative Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Teaching Overview

  • Dr. Marrazzo lectures on topics related to vaginal health and sexually transmitted infections.
  • Education And Training

  • Yale-New Haven Hospital, Internship
  • Yale-New Haven Hospital, Residency
  • University of Washington, Postdoctoral Fellowship
  • Master of Public Health in Epidemiology, University of Washington 1994
  • Doctor of Medicine, Thomas Jefferson University 1988
  • Bachelor of Arts in Biology, Harvard University 1984
  • Full Name

  • Jeanne Marrazzo